Innovative treatment for patients with aggressive systemic mastocytosis now available in Romania
Patients in Romania suffering from aggressive systemic mastocytosis have received important news. Health authorities have decided to include an innovative therapy on the list of reimbursed medicines, aimed at significantly improving the quality of life for those diagnosed with this rare disease.
Aggressive systemic mastocytosis is a complex hematological condition characterized by the abnormal accumulation of immune cells called mast cells in various organs. Until now, therapeutic options for these patients were limited, and access to state-of-the-art treatments was difficult for many of those affected.
The new treatment, which has already received approval for reimbursement, acts directly on the causes of the disease, offering an effective alternative to classic therapies. Specialists believe that this measure represents an essential step in aligning care standards in Romania with European ones, facilitating rapid patient access to essential medicines.
To benefit from this treatment, patients must be evaluated by multidisciplinary teams in specialized medical centers. Hematologists will determine if the therapy is suitable for each individual case, following the therapeutic protocols recently updated by the Ministry of Health.
This decision supports the medical community and patients, offering additional hope for the long-term management of a difficult condition. Authorities have announced that they will continue to monitor the availability of these medicines in pharmacies and hospitals to ensure that all those who need them receive them on time.